SCHEMBL21683300

SCHEMBL21683300

CC(C)(C)N(Cc1ccc(/C(N)=N\O)cc1)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.40
HDAC1 Q13547 7/20 0.39
HDAC2 Q92769 7/20 0.39
RAB9A P51151 4/20 0.39
GAA P10253 2/20 0.39
F2 P00734 1/20 0.38
NPC1 O15118 3/20 0.38
USP2 O75604 1/20 0.38
POLB P06746 1/20 0.38
GFER P55789 1/20 0.38
MAPK1 P28482 1/20 0.37
F10 P00742 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21683301 1.00 LMNA (0.45) LMNAMEN1KMT2AHTTL3MBTL1
SCHEMBL7864202 0.81 PRSS1 (0.50) LMNAMEN1KMT2AHTTL3MBTL1
SCHEMBL27207830 0.77 KMT2A (0.49) LMNAMEN1KMT2AHTTL3MBTL1
SCHEMBL335254 0.77 MEN1 (0.50) LMNAMEN1KMT2AHTTL3MBTL1
SCHEMBL15328453 0.77 MEN1 (0.50) LMNAMEN1KMT2AHTTL3MBTL1
SCHEMBL29573114 0.75 GRM2 (0.42) LMNAMEN1KMT2AL3MBTL1HDAC1
SCHEMBL6791575 0.75 GRM2 (0.42) LMNAMEN1KMT2AL3MBTL1HDAC1
SCHEMBL18527956 0.75 MEN1 (0.51) LMNAMEN1KMT2AHTTL3MBTL1
SCHEMBL356816 0.75 MEN1 (0.51) LMNAMEN1KMT2AHTTL3MBTL1
SCHEMBL20836738 0.75 HDAC1 (0.40) LMNAMEN1KMT2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486255-B2 Modulators of RAS GTPase TOSK, INC. (US) 2025-12-02 US disclosed
US-20240279206-A1 Modulators of RAS GTPase TOSK, INC. 2024-08-22 US disclosed
US-11945803-B2 Modulators of RAS GTPase TOSK, INC. (US) 2024-04-02 US disclosed
WO-2020033413-A2 MODULATORS OF RAS GTPASE TOSK, INC. (US) 2020-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486255-B2 Modulators of RAS GTPase KRAS, HRAS, NRAS LMNA 3457/4885MEN1 503/4885KMT2A 3199/4885
US-11945803-B2 Modulators of RAS GTPase KRAS, HRAS, NRAS LMNA 3457/4885MEN1 503/4885KMT2A 3199/4885
US-20240279206-A1 Modulators of RAS GTPase KRAS, HRAS, NRAS LMNA 3457/4885MEN1 503/4885KMT2A 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.